Can-Fite BioPharma Ltd. (TLV:CANF)
250.10
-11.30 (-4.32%)
Nov 12, 2026, 5:24 PM IST
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Can-Fite BioPharma the 42,028th largest employer in the world and 429th in Israel.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
241.31K ILS
Profits / Employee
-5.69M ILS
Market Cap
15.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Sep 30, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bonus BioGroup | 42 |
| BioLineRx | 24 |
| Matricelf | 15 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 5 |
| BioLight Life Sciences | 4 |
Can-Fite BioPharma News
- 13 hours ago - Can-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical Study - Nasdaq
- 15 hours ago - Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal - GlobeNewsWire
- 3 days ago - Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment Study - Nasdaq
- 3 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - Nasdaq
- 3 days ago - Can-Fite BioPharma Namodenoson patient reaches 10-year survival in liver cancer - TheFly
- 3 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - GlobeNewsWire
- 6 days ago - Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones - GlobeNewsWire
- 10 days ago - Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome - GlobeNewsWire